Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-312023-04-012falseThe principal activity of the company is that of a holding company.2falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 09768048 2023-04-01 2024-03-31 09768048 2022-04-01 2023-03-31 09768048 2024-03-31 09768048 2023-03-31 09768048 2022-04-01 09768048 c:Director2 2023-04-01 2024-03-31 09768048 d:CurrentFinancialInstruments 2024-03-31 09768048 d:CurrentFinancialInstruments 2023-03-31 09768048 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 09768048 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 09768048 d:ShareCapital 2024-03-31 09768048 d:ShareCapital 2023-03-31 09768048 d:ShareCapital 2022-04-01 09768048 d:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 09768048 d:RetainedEarningsAccumulatedLosses 2024-03-31 09768048 d:RetainedEarningsAccumulatedLosses 2022-04-01 2023-03-31 09768048 d:RetainedEarningsAccumulatedLosses 2023-03-31 09768048 d:RetainedEarningsAccumulatedLosses 2022-04-01 09768048 c:FRS102 2023-04-01 2024-03-31 09768048 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 09768048 c:FullAccounts 2023-04-01 2024-03-31 09768048 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 09768048 d:Subsidiary1 2023-04-01 2024-03-31 09768048 d:Subsidiary1 1 2023-04-01 2024-03-31 09768048 6 2023-04-01 2024-03-31 09768048 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure
Registered number: 09768048


B1 IMPLANT HOLDINGS LIMITED

UNAUDITED
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE YEAR ENDED 31 MARCH 2024

 
B1 IMPLANT HOLDINGS LIMITED
REGISTERED NUMBER:09768048

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Investments
 4 
100
100

Current assets
  

Debtors: amounts falling due within one year
 5 
-
15,587

Cash at bank and in hand
 6 
45
45

  
45
15,632

Creditors: amounts falling due within one year
 7 
(45)
(15,632)

  

Net assets
  
100
100


Capital and reserves
  

Called up share capital 
  
100
100


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



Babar Usman Wahid
Director

Date: 7 March 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 1

 
B1 IMPLANT HOLDINGS LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 April 2022
100
-
100


Comprehensive income for the year

Profit for the year
-
41,500
41,500


Contributions by and distributions to owners

Dividends: Equity capital
-
(41,500)
(41,500)



At 1 April 2023
100
-
100


Comprehensive income for the year

Profit for the year
-
39,500
39,500


Contributions by and distributions to owners

Dividends: Equity capital
-
(39,500)
(39,500)


At 31 March 2024
100
-
100


The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
B1 IMPLANT HOLDINGS LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

B1 Implant Holdings Limited is a private company, limited by shares, registered in England and Wales within the United Kingdom, company registration number 09768048. The Company's registered office address is 6th Floor, 2 London Wall Place, London, EC2Y 5AU. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The Company's functional and presentational currency is GBP, rounded to the nearest £1.

The following principal accounting policies have been applied:

 
2.2

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Page 3

 
B1 IMPLANT HOLDINGS LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)


2.6
Financial instruments (continued)

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due within the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.

Page 4

 
B1 IMPLANT HOLDINGS LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.7

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2023
100



At 31 March 2024
100





Subsidiary undertaking


The following was a subsidiary undertaking of the Company:

Name

Principal activity

Class of shares

Holding

B1 Implant Limited
Dental practice activities
Ordinary
100%

Page 5

 
B1 IMPLANT HOLDINGS LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5.


Debtors

2024
2023
£
£


Amounts owed by group undertakings
-
15,587



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
45
45



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Amounts owed to group undertakings
45
-

Other creditors
-
15,632



8.


Controlling party

The ultimate controlling parties of B1 lmplant Holdings Limited are the directors, Babar Wahid and Nazia Choudhury. 

 
Page 6